Skip to main content
SpringerLink
Log in

Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with enterococcus faecalis and escherichia coli in mice

Therapeutische Wirksamkeit von Cefpirom (HR 810) bei experimentellen Mischinfektionen durch Enterococcus faecalis und Escherichia coli in Mäusen

  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

The therapeutic effects of cefpirome (HR 810), a new cephalosporin, on mixed infections induced in mice withEnterococcus faecalis HL 1147 andEscherichia coli HL34 were compared with those of ampicillin (AMP), cefuzonam (CZON), and ceftazidime (CAZ). Cefpirome was more effective in protecting mice with systemic mixed infection (median effective dose, 52 mg/kg) than the other antibiotics (all more than 320 mg/kg). With increasing doses of cefpirome, the percentages of the animals havingE. faecalis andE. coli bacteremia were decreased. CZON and CAZ reduced onlyE. coli, and AMP failed to reduce both strains. In the mice with urinary tract mixed infection, cefpirome and CZON (40 mg/kg × 5, s. c.) significantly decreased the cfu/g kidney (p<0.01 vs. nontreated control), while AMP and CAZ were active only againstE. faecalis (p<0.05) andE. coli (p<0.01), respectively.

Zusammenfassung

Die therapeutische Wirksamkeit von Cefpirom (HR 810), einem neuen Cephalosporin, auf Mischinfektionen durchEnterococcus faecalis HL 1147 undEscherichia coli HL34 bei Mäusen wurde mit derjenigen von Ampicillin (AMP), Cefuzonam (CZON) und Ceftazidim (CAZ) verglichen. In seiner protektiven Wirkung gegen systemische Mischinfektionen bei Mäusen war Cefpirom mit einer mittleren effektiven Dosis von 52 mg/kg den anderen Antibiotika überlegen (alle Werte über 320 mg/kg). Der Prozentsatz der Tiere, bei denen eine Bakteriämie durchE. faecalis undE. coli auftrat, nahm mit zunehmend höheren Cefpirom-Dosen entsprechend ab. Durch CZON wurde nur eine Verminderung derE. coli-Infektionen erreicht und AMP hatte auf beide Stämme keine keimreduzierende Wirkung. Bei Mischinfektionen der Harnwege bei Mäusen führten Cefpirom und CZON (40 mg/kg × 5, s. c.) zu einer signifikanten Verminderung der Keimbildnerzahl (KBE/g Niere; p<0,01) im Vergleich zu unbehandelten Kontrollen. Für AMP ließ sich dagegen nur gegenE. faecalis (p<0,05) und für CAZ gegenE. coli (p<0,01) eine Wirksamkeit nachweisen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Klimek, J. J., Ajemian, E., Gracewski, J., Klemas, B., Rios, I., Maderazo, E., Quintiliani, R. Enterococcal infections in a large community hospital, with emphasis on bacteremia. Am. J. Infect. Cont. 8 (1980) 58–61.

    Google Scholar 

  2. Shimada, K., Adachi, K., Tanaka, K., Sasaki, M., Hatakeyama, T., Kamijo, H., Inamatsu, T., Urayama, K., Oka, S. Enterococcal bacteremia. I. Speciation and antibiotic susceptibilities of 49 strains of enterococcus isolated from blood cultures. Chemotherapy (Japan) 32 (1984) 435–438.

    Google Scholar 

  3. Kaneko, H., Kitahara, K., Tominaga, T., Kishi, H., Niijima, T., Iwamoto, S. Clinical studies ofStreptococcus faecalis in urinary tract infections. Chemotherapy (Japan) 32 (1984) 685–691.

    Google Scholar 

  4. Fujimura, N. A study for urinary isolates of long-term catheterization in urological field. Nishinihon J. Urol. 41 (1979) 871–879.

    Google Scholar 

  5. Muytjens, H. L., van der Ros-van de Repe, J. Comparative activities of 13 ß-lactam antibiotics. Antimicrob. Agents Chemother. 21 (1982) 925–934.

    Google Scholar 

  6. Rolinson, G. N. ß-Lactam antibiotics. J. Antimicrob. Chemother. 17 (1986) 5–36.

    Google Scholar 

  7. Yu, V. L. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann. Intern. Med. 94 (1981) 784–785.

    Google Scholar 

  8. Kawada, Y. The third-generation cephem antibiotics: Their availability in urology. Diagnosis and Treatment 71 (1983) 1405–1410.

    Google Scholar 

  9. Seibert, G., Limbert, M., Winkler, I., Dick, T. The antibacterial activityin vitro and ß-lactamase stability of the new cephalosporins HR 810 in comparison with five other cephalosporins and two aminoglycosides. Infection 11 (1983) 275–279.

    Google Scholar 

  10. Arai, S., Kobayashi, S., Hayashi, S., Fujimoto, K. In vitro antimicrobial activity of cefpirome, a new cephalosporin with a broad antimicrobial spectrum. Japan. J. Antibiot. 40 (1987) 969–982.

    Google Scholar 

  11. Eng, R. H. K., Cherubin, C. E., Smith, S. M., Buccini, F., Harris, R. In vitro andin vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistantStaphylococcus aureus andStreptococcus faecalis. J. Antimicrob. Chemother. 23 (1989) 373–381.

    Google Scholar 

  12. Richmond, M. H., Sykes, R. B. The ß-lactamases of gram-negative bacteria and their possible physiological role. Adv. Microb. Physiol. 9 (1973) 31–88.

    Google Scholar 

  13. Japan. Society of Chemotherapy Method for MIC determination (2nd revision). Chemotherapy (Japan) 29 (1981) 76–79.

    Google Scholar 

  14. Kawasaki, K., Sekiguchi, K., Ogawa, M., Tsuji, A., Goto, S. Relationship between opportunistic pathogen and protective function of the host. Enhanced sensitivities to various microorganisms of experimentally induced leukopenic mice and therapeutic effects of antibiotics. Chemotherapy (Japan) 28 (1980) 14–21.

    Google Scholar 

  15. Oomori, Y., Ogawa, M., Miyazaki, S., Goto, S. Fundamental studies on experimental urinary tract infection with various species of gramnegative bacilli. Chemotherapy (Japan) 30 (1982) 1237–1250.

    Google Scholar 

  16. Klesel, N., Limbert, M., Schrinner, E., Seeger, K., Seibert, G., Winkler, I. Chemotherapeutic properties of the new cephalosporin antibiotic HR 810 in laboratory animals. Infection 12 (1984) 286–292.

    Google Scholar 

  17. Sami, A. A., Abd-El-Hamid, T., Sabbour, M. S. Incidence of beta-lactamase producingE. coli in urinary tract infections. Chemioterapia IV (1985) 429–430.

    Google Scholar 

  18. Ogawa, M., Uji, T., Miyazaki, S., Goto, S. Study of the pathogenicity ofEnterococcus faecalis. Experimental mice mixed infection withE. faecalis and other organisms. J. Japan. Assoc. Infect. Dis. 62 (1988) 217–225.

    Google Scholar 

  19. Kobayashi, S., Arai, S., Hayashi, S., Fujimoto, K. ß-Lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum. Antimicrob. Agents Chemother. 30 (1986) 713–718.

    Google Scholar 

  20. Ogashiwa, M., Inoue, M., Mitsuhashi, S. In vitro andin vivo antibacterial activity of ceftazidime. Chemotherapy (Japan) 31 S-3 (1983) 1–16.

    Google Scholar 

  21. Hikida, M., Mitsuhashi, S., Inoue, M. In vitro antibacterial activity of L-105. Chemotherapy (Japan) 34 S-3 (1986) 1–16.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharma Research Laboratories, Hoechst Japan Limited, 1-3-2 Minamidai, 350, Kawagoe, Saitama, Japan

    S. Arai &  S. Hayashi

Authors
  1. S. Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arai, S., Hayashi, S. Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with enterococcus faecalis and escherichia coli in mice. Infection 18, 186–190 (1990). https://doi.org/10.1007/BF01642112

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01642112

Keywords

Search

Navigation